There can be no doubt that oncology drug development is entering a critical phase. However, developing Oncology products is full of major challenges that need to be met head on in order to bring safe and effective treatments to market.
Conference themes include:
How can biomarkers be used to improve predictivity in early research?
Can translational medicine be used to improve the bottlenecks in clinical research?
What novel target classes show the most promise?
Is the market’s expectations achievable and how will they be met?
Who will pay for innovation?
This unique meeting will address the critical strategic, scientific and regulatory issues in the development of targeted oncology therapeutics.
Who will attend?
Pharmaceutical Manufacturers
Biotechnology Companies
Academic Institutions
Heads, Directors and Vice Presidents of:
*Oncology Clinical Trials/Product *development
*Clinical Trials
*Clinical Research
*Drug Development
*R&D
*Licensing
*Business Development
The speaker line-up is dominated by CEOs, industry experts, leading oncology professionals and department heads in the US and the rest of the World.
With unparalleled coverage of important critical issues and a selection of highly relevant case studies, this event is a knowledge experience as well as the premier networking event. Mark your calendars for these dates!
